nL-SCN2A-002

nL-SCN2A-002 is a personalized antisense oligonucleotide (ASO) drug developed for the treatment of rare pediatric genetic diseases associated with pathogenic gain-of-function mutations in the SCN2A gene, specifically developmental epileptic encephalopathy. The drug is designed to selectively bind and lower expression of the mutant SCN2A transcript, thereby reducing toxic sodium channel activity caused by the mutation. This approach aims to address severe neurodevelopmental disorders that are refractory to standard antiepileptic drugs. The therapy is highly individualized, created for a single patient based on their unique genetic variant, and represents a precision medicine strategy for "nano-rare" diseases where commercial drug development is not feasible. The developer and active organization behind this therapy is n-Lorem Foundation[1][6][8].